72
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer

, , , , , & show all
Pages 5653-5665 | Published online: 03 Dec 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Benedito A Carneiro, Jason B Kaplan, Jessica K Altman, Francis J Giles & Leonidas C Platanias. (2015) Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biology & Therapy 16:5, pages 648-656.
Read now

Articles from other publishers (4)

Abdullah K. Alshememry, Nasser B. Alsaleh, Nora Alkhudair, Rami Alzhrani & Aws Alshamsan. (2022) Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview. Frontiers in Pharmacology 13.
Crossref
Joaquín Yanes-Díaz, Raquel Palao-Suay, María Rosa Aguilar, Juan Ignacio Riestra-Ayora, Antonio Ferruelo-Alonso, Luis Rojo del Olmo, Blanca Vázquez-Lasa, Ricardo Sanz-Fernández & Carolina Sánchez-Rodríguez. (2021) Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell Carcinoma. Pharmaceutics 13:8, pages 1242.
Crossref
Wenpeng Cao, Zhirui Zeng, Runsang Pan, Hao Wu, Xiangyan Zhang, Hui Chen, Yingjie Nie, Zijiang Yu & Shan Lei. (2021) Hypoxia-Related Gene FUT11 Promotes Pancreatic Cancer Progression by Maintaining the Stability of PDK1. Frontiers in Oncology 11.
Crossref
Tania Maffucci & Marco Falasca. (2020) Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling. International Journal of Molecular Sciences 21:19, pages 7198.
Crossref